# 21 U.S.C. 360bb Designation of drugs for rare diseases or conditions

21 U.S.C. 360bb Designation of drugs for rare diseases or conditions, “Designation of drugs for rare diseases or conditions”, is a U.S. Code section of [Part B—Drugs for Rare Diseases or Conditions](https://ontology.bommaritollc.com/id/01a0f06c-cb98-7071-a43e-8d27fa14a067); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part B—Drugs for Rare Diseases or Conditions](https://ontology.bommaritollc.com/id/01a0f06c-cb98-7071-a43e-8d27fa14a067)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 360bb](https://ontology.bommaritollc.com/id/01a0f06c-cd20-7186-807f-5a7d7aa72f2d)
- `eli:cites`:
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partB-sec360bb](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe45360abf2)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d15d-774b-a7b8-f4a1eb5d4b6f)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d79-7146-bc6d-206a33be4ded)
  - [evidence from https://www.govinfo.gov/link/uscode/21/360bb?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe35-7634-950c-833032f28e57)
- `schema:isPartOf`: [Part B—Drugs for Rare Diseases or Conditions](https://ontology.bommaritollc.com/id/01a0f06c-cb98-7071-a43e-8d27fa14a067)
- `schema:legislationIdentifier`: 21 U.S.C. 360bb
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Designation of drugs for rare diseases or conditions
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/360bb?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/360bb?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 360bb Designation of drugs for rare diseases or conditions

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/360bb?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partB-sec360bb) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (15; `eli:cites`):
  - [21 U.S.C. 355a Pediatric studies of drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd9-779c-b02d-f70feff4a7a0)
  - [21 U.S.C. 355c Research into pediatric uses for drugs and biological products](https://ontology.bommaritollc.com/id/01a0f06c-ccdc-7622-b131-6752c5c696e4)
  - [21 U.S.C. 360cc Protection for drugs for rare diseases or conditions](https://ontology.bommaritollc.com/id/01a0f06c-cd20-7186-807f-5a7f0a266149)
  - [21 U.S.C. 360dd Open protocols for investigations of drugs for rare diseases or conditions](https://ontology.bommaritollc.com/id/01a0f06c-cd21-721e-9ba1-2c86bb3f2906)
  - [21 U.S.C. 360ee Grants and contracts for development of drugs for rare diseases and conditions](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44)
  - [21 U.S.C. 360ff Priority review to encourage treatments for rare pediatric diseases](https://ontology.bommaritollc.com/id/01a0f06c-cd25-70dc-81b8-fa28ceb7a6e8)
  - [21 U.S.C. 360ff-1 Targeted drugs for rare diseases](https://ontology.bommaritollc.com/id/01a0f06c-cd26-7241-a723-3bb1e8bc9291)
  - [21 U.S.C. 379h Authority to assess and use drug fees](https://ontology.bommaritollc.com/id/01a0f06c-cd9d-7067-a1f7-38b3a2d65388)
  - [26 CFR 1.28-1 Credit for clinical testing expenses for certain drugs for rare diseases or conditions.](https://ontology.bommaritollc.com/id/01a0f099-886f-7163-b340-1c0ecea27a71)
  - [42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d)
  - [42 U.S.C. 1395l Payment of benefits](https://ontology.bommaritollc.com/id/01a0f07c-e0c2-7095-ad6d-d895e786c4df)
  - [42 U.S.C. 236 Orphan Products Board](https://ontology.bommaritollc.com/id/01a0f07c-d8fc-7062-9749-1d5dcb64a256)
  - [42 U.S.C. 256b Limitation on prices of drugs purchased by covered entities](https://ontology.bommaritollc.com/id/01a0f07c-d9be-725f-881b-75132e9a9101)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 287 National Center for Advancing Translational Sciences](https://ontology.bommaritollc.com/id/01a0f07c-db14-7251-8b39-1e3da451f808)
- Amended by (4; `eli:amends`):
  - [Pub. L. 100-290](https://ontology.bommaritollc.com/id/01a0f06c-d330-73fb-854a-f0dcc4cca24d)
  - [Pub. L. 105-115](https://ontology.bommaritollc.com/id/01a0f06c-d29f-7443-a96a-3934363a8187)
  - [Pub. L. 98-551](https://ontology.bommaritollc.com/id/01a0f06c-d32f-7664-b81d-e9af2d1a882f)
  - [Pub. L. 99-91](https://ontology.bommaritollc.com/id/01a0f06c-d32d-7698-b93c-3488d74aef5d)
- Rules made under it (2; `eli:based_on`):
  - [21 CFR Part 316—Orphan drugs](https://ontology.bommaritollc.com/id/01a0f094-b84f-746b-a63a-3c771d0858a5)
  - [21 CFR Part 4—Regulation of combination products](https://ontology.bommaritollc.com/id/01a0f094-b7dd-74b7-ac14-bf82566fc9ed)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 97-414](https://ontology.bommaritollc.com/id/01a0ee1d-951e-70e8-a68c-4a5cc7f187f7)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf)
Cite as: 21 U.S.C. 360bb Designation of drugs for rare diseases or conditions. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
